Omega-3 Supplements and Heart Outcomes in People on Dialysis
This meta-analysis combined results from randomized controlled trials testing omega-3 fatty acid (n-3 PUFA) supplements against placebo in adults undergoing hemodialysis, a group known to face high rates of cardiovascular problems.
The pooled data showed that omega-3 supplementation did not significantly lower the risk of death from any cause. However, it was linked to a meaningful reduction in deaths specifically related to cardiovascular disease, fewer heart attacks (fatal and non-fatal), and fewer complications involving the vascular access sites used for dialysis.
The authors note that much of the evidence comes from one large trial, so these findings should be viewed as promising but not yet fully confirmed. They call for additional large, well-designed trials to verify the results.
What this means for you
For people undergoing hemodialysis, this analysis suggests omega-3 supplementation may be associated with fewer cardiovascular-related events, though it did not show a clear benefit for overall survival. As the evidence is concentrated in one major study, these results are considered preliminary and worth discussing with a healthcare provider rather than a settled conclusion.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolThis summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.